Related Experiment Video
Updated: Jun 5, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled
Hans Gelderblom1, Rachel C Jinks, Matthew Sydes
1Department of Clinical Oncology, Leiden University Medical Center, The Netherlands.
European Journal of Cancer (Oxford, England : 1990)
|January 11, 2011
Summary
Early recurrence of osteosarcoma significantly impacts survival. Good histological response to chemotherapy and local-only recurrence are associated with better outcomes in patients with recurrent extremity osteosarcoma.
Area of Science:
- Oncology
- Orthopedic Oncology
- Clinical Trials
Background:
- Recurrence of osteosarcoma is often fatal, making prognostic factors crucial for survival.
- Identifying predictors of survival in recurrent osteosarcoma is essential for patient management.
Purpose of the Study:
- To investigate prognostic factors for post-recurrence survival (PRS) in patients with extremity osteosarcoma.
- To analyze the impact of recurrence timing, histological response, and recurrence site on survival outcomes.
Main Methods:
- Analysis of combined data from 1067 patients across 3 European Osteosarcoma Intergroup randomized controlled trials (1983-2002).
- Patients received pre- and post-operative chemotherapy for resectable, non-metastatic, high-grade extremity osteosarcoma.
- Standard survival analysis methods were used to assess post-recurrence survival.
Main Results:
- Median recurrence-free survival was 31 months; 8 recurrences occurred >5 years post-diagnosis.
- Patients with recurrence within 2 years had a worse prognosis than those recurring later.
- Good initial histological response to chemotherapy and local-only recurrence were linked to better overall survival after recurrence.
Conclusions:
- Early recurrence in extremity osteosarcoma is strongly associated with poor survival.
- Positive histological response to neoadjuvant chemotherapy and local-only recurrence predict improved post-recurrence survival.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...